MDxHealth SA
NASDAQ:MDXH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
MDxHealth SA
Common Shares Outstanding
MDxHealth SA
Common Shares Outstanding Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Shares Outstanding | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
MDxHealth SA
NASDAQ:MDXH
|
Common Shares Outstanding
$51.4m
|
CAGR 3-Years
47%
|
CAGR 5-Years
41%
|
CAGR 10-Years
28%
|
|
|
Galapagos NV
AEX:GLPG
|
Common Shares Outstanding
€65.9m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
Oxurion NV
XBRU:OXUR
|
Common Shares Outstanding
€3.2m
|
CAGR 3-Years
-60%
|
CAGR 5-Years
-39%
|
CAGR 10-Years
N/A
|
|
|
Celyad Oncology SA
XBRU:CYAD
|
Common Shares Outstanding
€44.8m
|
CAGR 3-Years
26%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
|
European Medical Solutions
XBRU:ALEMS
|
Common Shares Outstanding
€4.2m
|
CAGR 3-Years
0%
|
CAGR 5-Years
133%
|
CAGR 10-Years
N/A
|
|
MDxHealth SA
Glance View
MDxHealth SA engages in the development and commercialization of molecular diagnostic products for personalized cancer treatment. The company is headquartered in Herstal, Liege. The company went IPO on 2006-06-26. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The firm's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.
See Also
What is MDxHealth SA's Common Shares Outstanding?
Common Shares Outstanding
51.4m
USD
Based on the financial report for Dec 31, 2025, MDxHealth SA's Common Shares Outstanding amounts to 51.4m USD.
What is MDxHealth SA's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 10Y
28%
Over the last year, the Common Shares Outstanding growth was 4%. The average annual Common Shares Outstanding growth rates for MDxHealth SA have been 47% over the past three years , 41% over the past five years , and 28% over the past ten years .
